Petra Pharma names new executive leadership team and Scientific Advisory Board.
M2 EQUITYBITES-July 28, 2017-Petra Pharma names new executive leadership team and Scientific Advisory Board
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Petra Pharma Corporation, an oncology and metabolic diseases drug development company, announced yesterday that it has chosen an executive leadership team and named a Scientific Advisory Board.
The company advanced from the Accelerator Corporation, a life science investment and management firm, and will be led by Brian O'Callaghan, chief executive officer, David McElligott, PhD, chief scientific officer, David Renas, chief financial officer and Paul Sekhri, chairman of the board.
Nathanael Gray, PhD, Harvard Medical School and Dana-Farber Cancer Institute, and Lewis Cantley, PhD, Weill Cornell Medicine, the scientific co-founders of Petra Pharma, have officially joined the company's Scientific Advisory Board.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jul 28, 2017|
|Previous Article:||Qiagen reports Q2 2017 financial results.|
|Next Article:||Intec Pharma names new chief operating officer.|